Zogenix Scoops Up FDA Fast Track Status for ZX008

The FDA has fast tracked Zogenix’s ZX008 to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy.

The designation qualifies Zogenix for more communication with the agency and a potentially quicker review and approval process. Zogenix notes that a second Phase 3 study of ZX008 will begin in Europe this quarter.